$PROK News

ProKidney Appoints Kenneth Locke as Chief Technical Officer

HC Wainwright & Co. Reiterates Buy on ProKidney, Maintains $12 Price Target

ProKidney Corp. (PROK) Reports Q1 Loss, Tops Revenue Estimates

ProKidney Reports First Quarter 2026 Financial Results and Business Highlights

ProKidney Q1 EPS $(0.14), Inline, Sales $226.000K Beat $143.667K Estimate

ProKidney (PROK) Appoints Greg Madison as CCO to Lead Commercial Strategy for Rilparencel

What Makes ProKidney Corp. (PROK) So Attractive

ProKidney Expands Senior Leadership Team with Appointment of Greg Madison as Chief Commercial Officer

ProKidney Reports Full Year 2025 Financial Results and Business Highlights

ProKidney Q4 EPS $(0.14) Misses $(0.11) Estimate, Sales $225.000K Beat $83.333K Estimate

Prokidney Updates Phase 3 REGEN-006 Trial Enrollment Of ~470 Subjects

ProKidney Stock: Differentiated CKD Approach Positions Rilparencel Favorably

ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

ProKidney Corp. (PROK) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow

ProKidney Corp. (PROK) Positioned to Redefine Chronic Kidney Disease Treatment, Believes H.C. Wainwright

HC Wainwright & Co. Initiates Coverage On ProKidney with Buy Rating, Announces Price Target of $12

While insiders own 18% of ProKidney Corp. (NASDAQ:PROK), retail investors are its largest shareholders with 50% ownership

ProKidney Reports Third Quarter 2025 Financial Results and Provides Regulatory and Clinical Updates

ProKidney Q3 EPS $(0.12) Beats $(0.14) Estimate, Sales $217.000K Beat $44.250K Estimate

ProKidney Presents Full Results from the Phase 2 REGEN-007 Trial of Rilparencel at the American Society of Nephrology Kidney Week 2025